Premium
Absolute CD4 + T‐lymphocyte and CD34 + stem cell counts by single‐platform flow cytometry: the way forward
Author(s) -
David Barnett,
Vivian Granger,
Liam Whitby,
Ian Storie,
John T. Reilly
Publication year - 1999
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.1999.01632.x
Subject(s) - enumeration , immunophenotyping , stem cell , cd34 , flow cytometry , lymphocyte , immunology , microbiology and biotechnology , nuclear medicine , biology , medicine , mathematics , combinatorics
To determine the potential advantage of single‐platform technology in the enumeration of CD4 + T lymphocyte and CD34 + stem cells, data has been analysed from the UK NEQAS for Leucocyte Immunophenotyping schemes. The inter‐laboratory CVs for CD4 + T lymphocyte counts were consistently lower for single‐platform (mean 13.7%, range 10–18.3%) compared to dual‐platform methodology (mean 23.4%, range 14.5–43.7%). Subgroup analysis of single‐platform users demonstrated mean overall inter‐laboratory CVs of 17.2%, 13% and 7.1% for the FlowCount, TruCount and volumetric approach respectively. The lowest inter‐laboratory CVs obtained for a single sample by each single platform approach were 4% (TruCount), 4.4% (volumetric), 4.6% (FACSCount) and 12.7% (FlowCount). Similarly, the mean inter‐laboratory CV for CD34 + stem cell enumeration using non‐standardized single‐platform approaches was 18.6% (range 3.1–36.9%) compared to 28.6% (range 19–44.2%) for the dual‐platform technology. Our results suggest absolute cell subset enumeration should be performed by single‐platform technology and that such an approach should improve the quality control of multi‐centre clinical trial data for CD4 + T lymphocyte and CD34 + stem cells.